The Endpoints News poll: Should the FDA panel back an approval for aducanumab, or should they send Biogen packing?
There’s been a considerable amount of back-and-forth over the relative merits, or lack thereof, in Biogen’s application to market the Alzheimer’s drug aducanumab.
Biogen execs have been absolutely steadfast — at least after their second take of the data — that they’ve proven that a consistent high dose of their drug can moderate disease progression. Critics say it’s a post hoc mess filled with bias and blown so far off track that Biogen can’t come close to meeting the agency’s requirement of positive data from 2 well designed studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
